Short- and Long-term Outcomes of an Acellular Dermal Substitute versus Standard of Care in Burns and Reconstructions: A Phase I/II Intrapatient Randomized Controlled Trial
Authors:
- Kim L. M. GardienKGKim L. M. Gardien
- Anouk PijpeAPAnouk Pijpe
- Katrien M. BrouwerKBKatrien M. Brouwer
- Matthea StoopMSMatthea Stoop
- Simarjeet K. SinghSSSimarjeet K. Singh
- Floyd W. TimmermansFTFloyd W. Timmermans
- Marcel Bas VligMVMarcel Bas Vlig
- Paul P. M. van ZuijlenPZPaul P. M. van Zuijlen
- Esther MiddelkoopEMEsther Middelkoop
Open Access
- 1 October 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Advances in Skin & Wound Care
- Vol. 36 (10) , 540-548
Abstract
OBJECTIVE: Dermal substitutes promote dermal regeneration and improve scar quality, but knowledge gaps remain regarding their efficacy and indications for use. The authors investigated the safety and short- and long-term efficacy of an acellular dermal substitute in patients with full-thickness wounds. METHODS: This intrapatient randomized controlled, open-label, phase I (safety) and phase II (efficacy) study compared treatment with Novomaix (Matricel GmbH), a dermal collagen/elastin-based scaffold, with split-thickness skin graft (STSG) only. The primary safety outcome was graft take at 5 to 7 days postsurgery. Postsurgical scar quality was assessed by measuring elasticity, color, and scores on the Patient and Observer Scar Assessment Scale at 3 months, 12 months, and 6 years. RESULTS: Twenty-five patients were included, of which 24 received treatment allocation. Graft take and wound healing were statistically significantly lower/delayed in the dermal matrix group compared with STSG alone (P < .004). Serious adverse events were delayed epithelialization in four dermal matrix and three STSG study areas. At 12 months postsurgery, skin extension (P = .034) and elasticity (P = .036) were better for the dermal matrix group compared with the group receiving STSG alone. Other scar quality parameters at 12 months and 6 years did not differ between treatment arms. CONCLUSIONS: The dermal substitute was a safe treatment modality for full-thickness wounds. Compared with STSG alone, time to wound healing was slightly increased. Nevertheless, scar quality at 12 months seemed somewhat improved in the wounds treated with the dermal substitute, indicative of enhanced scar maturation. In the long term, final scar quality was similar for both treatment modalities.Keywords
This publication has 37 references indexed in Scilit:
- Rasch analysis of the Patient and Observer Scar Assessment Scale (POSAS) in burn scarsQuality of Life Research, 2011
- Topical negative pressure therapy: Does it accelerate neovascularisation within the dermal regeneration template, Integra? A prospective histological in vivo studyBurns, 2010
- Dermal Substitution in Acute Burns and Reconstructive Surgery: A 12-Year Follow-UpPlastic and Reconstructive Surgery, 2010
- Use of a novel collagen matrix with oriented pore structure for muscle cell differentiation in cell culture and in graftsJournal of Cellular and Molecular Medicine, 2008
- In Vitro Assessment of Axonal Growth Using Dorsal Root Ganglia Explants in a Novel Three-Dimensional Collagen MatrixTissue Engineering, 2007
- Synthetic scaffold morphology controls human dermal connective tissue formationJournal of Biomedical Materials Research Part A, 2005
- Colour evaluation in scars: tristimulus colorimeter, narrow-band simple reflectance meter or subjective evaluation?Burns, 2004
- Skin elasticity meter or subjective evaluation in scars: a reliability assessmentBurns, 2004
- Interactions of 3T3 fibroblasts and endothelial cells with defined pore featuresJournal of Biomedical Materials Research, 2002
- Graft Survival and Effectiveness of Dermal Substitution in Burns and Reconstructive Surgery in a One-Stage Grafting ModelPlastic and Reconstructive Surgery, 2000